Panadol

Panadol is an international over-the-counter analgesic brand whose core products contain paracetamol, also known as acetaminophen. It is used principally for the temporary relief of common mild-to-moderate pain and fever, including headaches, muscular aches, toothache, backache and symptoms associated with colds and flu. Depending on the market, the portfolio includes standard tablets, faster-dissolving formulations, combination products and variants containing caffeine or other active ingredients. Product composition, indications, pack formats and regulatory status vary by country, so the brand is not a single globally identical medicine. The brand was launched in 1955 by Sterling Drug as a paracetamol-only pain-relief medicine. Its positioning helped distinguish it from older analgesics based on aspirin or other ingredients, and the name subsequently became established across numerous international consumer-health markets. In 1994, SmithKline Beecham acquired Sterling and thereby acquired Panadol. The brand later became part of the consumer-health portfolio assembled by GlaxoSmithKline through the combination of the Glaxo Wellcome and SmithKline Beecham businesses and subsequent consumer-health transactions. In 2019, GSK and Pfizer agreed to combine their consumer-health operations in a joint venture. Panadol joined a portfolio that also included brands such as Sensodyne, Voltaren, Centrum and Advil. The venture was later named Haleon. Haleon was separated from GSK and listed as an independent public company in July 2022, making Panadol a flagship brand within a standalone consumer-health group rather than a brand housed directly within GSK’s pharmaceutical business. Panadol operates across developed and emerging markets, with particularly strong commercial relevance reported in the Middle East and Africa, Australia, Southeast Asia and Taiwan. The range is sold through pharmacies, supermarkets, convenience stores, e-commerce and other retail channels. Local versions include Panadol Extra, Panadol Advance, Panadol Rapid and Panadol Cold + Flu, although availability and formulation differ by market. The brand’s communications have evolved from functional demonstrations of pain relief and product technology toward broader emotional and cultural themes, including the value of returning to everyday activities after pain subsides. Because Panadol is an over-the-counter medicine, its use is subject to label directions and local health regulations. Excessive paracetamol intake can cause serious liver injury, particularly when consumers combine multiple medicines containing the same ingredient. The brand therefore operates within a highly regulated category where safety communication, accurate claims, responsible dosing information and differentiation from generic alternatives are central to its long-term reputation. Today, Panadol remains an active Haleon brand and one of the company’s principal pain-relief franchises.

Panadol was introduced in 1955 by Sterling Drug as a paracetamol-only medicine. Its launch placed the brand in the expanding consumer-health market for non-prescription pain relief and gave it a product identity distinct from analgesics based on aspirin. The brand name subsequently spread across a range of national markets, where local regulatory requirements and consumer preferences shaped the available formulations. A major ownership transition occurred in 1994, when SmithKline Beecham acquired Sterling and its brands, including Panadol. Panadol later became part of the broader consumer-health portfolio associated with the formation of GlaxoSmithKline. Glaxo Wellcome and SmithKline Beecham had merged in 2000, and GSK continued to develop consumer-health brands alongside its prescription medicines and vaccines businesses. GSK subsequently expanded and reorganised its consumer-health operations through strategic transactions. In 2019, GSK and Pfizer agreed to combine their consumer-health businesses in a joint venture. The transaction brought together GSK brands such as Panadol, Sensodyne and Voltaren with Pfizer’s Advil and other products. The joint venture was led by Brian McNamara and was designed as a focused global consumer-health company, with GSK initially retaining control. The new company was named Haleon in 2022. GSK announced that Haleon would contain leading brands including Panadol, Sensodyne, Voltaren and Centrum, and would be headquartered in Weybridge in the United Kingdom. Haleon was separated from GSK and listed on the London Stock Exchange in July 2022. This restructuring changed Panadol’s corporate setting: it remained a Haleon brand, but Haleon operated as an independent consumer-health company rather than as a division inside GSK. Panadol’s commercial history has combined product-line extension with sustained advertising investment. Variants have included standard paracetamol products, Panadol Extra, Panadol Advance and Panadol Rapid, with some markets also offering cold-and-flu combinations. Panadol Advance advertising highlighted the Optizorb disintegration system and faster product dispersion relative to ordinary paracetamol products, while regional campaigns have used more emotional, humorous and experiential approaches. The brand has been promoted throughout Europe, the Middle East, Africa, Australia and Asia-Pacific, with the specific portfolio differing by country. Haleon’s 2022 reporting identified Panadol as a strong performer in pain relief, particularly in the Middle East and Africa, Australia, Southeast Asia and Taiwan. The company attributed momentum partly to brand activation and the Take Care Panadol campaign, which was extended across more than one market. In parallel, Haleon has pursued group-wide efficiency measures, including workforce restructuring announced in 2023. These corporate actions did not represent a change in Panadol’s medical identity or a product withdrawal. The brand remains active. Its continued development is shaped by the mature and competitive nature of the analgesics category, competition from branded and generic alternatives, pharmacy and retail distribution, local medicine regulation and the need to communicate responsible paracetamol use. Panadol’s enduring proposition is practical pain and fever relief, supplemented by formulations and communications intended to help consumers resume normal activities.

• 2022

  Haleon name and separation announced

  [3]GSK announces the Haleon namegsk.com

  GSK identifies Haleon as the future independent consumer-health company containing Panadol and other leading brands.

• 2022

  Haleon lists independently

  [2]GSK introduces Haleon to investorsgsk.com

  Haleon is separated from GSK and listed on the London Stock Exchange, with Panadol as a core brand.

• 2019

  GSK and Pfizer create a consumer-health joint venture

  [2]GSK introduces Haleon to investorsgsk.com

  Panadol becomes part of the combined consumer-health venture formed by GSK and Pfizer.

• 1994

  SmithKline Beecham acquires Sterling

  [1]Haleon historyhaleon.com

  SmithKline Beecham acquires Sterling and adds Panadol to its consumer-health portfolio.

• 1955

  Panadol launches

  [1]Haleon historyhaleon.com

  Sterling Drug launches Panadol as a paracetamol-only pain-relief medicine.

Trusted, accessible relief for everyday pain and fever, combining familiar paracetamol-based treatment with market-specific formulations and convenience features.

• Paracetamol analgesic

  Panadol Standard

  The core Panadol proposition consists of paracetamol-based products for temporary relief of common mild-to-moderate pain and fever. Exact strength, dosage form, indications and pack presentation depend on the national market and applicable medicine regulations.

• Combination analgesic

  Panadol Extra

  Panadol Extra is a market-specific enhanced pain-relief line generally associated with paracetamol combined with caffeine. It is promoted for headaches and other everyday pain, but its formulation and approved claims vary between countries. Consumers are expected to follow the local label and avoid duplicating paracetamol from other medicines.

• Fast-dispersing analgesic

  Panadol Advance

  Panadol Advance is a formulation marketed in some countries with the Optizorb system. Brand communications have focused on tablet disintegration and the intended delivery of paracetamol for pain relief. Availability, product claims and formulation are country-specific.

• Rapid-dissolving analgesic

  Panadol Rapid

  Panadol Rapid is a locally marketed fast-dissolving or rapid-action variant intended to provide convenient paracetamol-based relief. The product name does not establish identical performance or composition worldwide; consumers should rely on the package information in their market.

• Cold and flu medicine

  Panadol Cold + Flu

  Panadol Cold + Flu products combine pain or fever relief with treatment of selected cold and flu symptoms. Formulations differ substantially by country and may contain additional active ingredients, making label checking particularly important when used with other medicines.

• 2023Not that pain though

  Costa Rica

  Leo Burnett used humorous outdoor and print executions for Panadol Extra and Panadol Cold + Flu, contrasting treatable physical discomfort with awkward life situations that medicine cannot solve.

  Source
• 2022Release Starts Here

  United Kingdom · Ireland

  Created by WPP, this integrated platform portrayed the point at which pain begins to recede as an emotional and practical transition. The programme used television, digital media, social edits, retail activity and pharmacy activation.

  Outcome. It positioned Panadol around an inclusive, purpose-led interpretation of relief rather than relying only on a technical product demonstration.

  Source
• 2021More Laughs. Less Pain

  United Kingdom

  Panadol connected pain relief with the mood benefits of laughter through outdoor and digital advertising, a partnership with comedy platform NextUp and support for the Live Comedy Association’s Save Live Comedy initiative.

  Outcome. The campaign sought to encourage more laughter after the restrictions and disruption of the COVID-19 period while reinforcing Panadol’s pain-relief positioning.

  Source
• 2019Hit The Pain

  Egypt

  MAWADA created a print campaign for Panadol Extra that presented the product as a strong response to headache and other pain.

  Source
• 2018Toughies

  Nigeria

  Panadol Extra’s campaign celebrated people who persist through demanding work and help others, linking their resilience and daily activities with the product’s pain-relief role.

  Source
• 2010Visible Man

  United Kingdom

  An Ogilvy television campaign for Panadol Advance used computer-generated visualisation to explain the Optizorb tablet system and the product’s claimed faster dispersion compared with ordinary paracetamol.

  Outcome. The campaign was updated to reference Panadol Advance receiving a Pain Relief Product of the Year award based on a consumer survey.

  Source
• Pain is Everywhere

  Middle East · Argentina

  Grey Argentina and Grey Dubai used print and social executions to depict ordinary, easily overlooked moments that cause pain, moving away from exaggerated pharmaceutical advertising conventions.

  Source
• Art of Release

  United Arab Emirates

  An experiential activation in Dubai invited visitors to describe what relief felt like and used AI-generated visual content and digital screens to interpret those descriptions in installations at Mall of the Emirates and JBR the Beach.

  Outcome. The activation made the subjective experience of pain relief the centre of the brand experience and gave participants personalised visual outputs.

  Source

• 2022

  Haleon separation and listingStrategy

  Background

  GSK sought to create a dedicated consumer-health company with a portfolio of established global brands.

  Action taken

  Haleon was created as the independent corporate home for Panadol and listed on the London Stock Exchange.

  Aftermath

  Panadol continued as one of Haleon’s major pain-relief brands, with Haleon responsible for its global consumer-health strategy.

  Source

• 2019

  GSK and Pfizer combine consumer-health operationsM&A

  Background

  The transaction was intended to create a focused global consumer-health company combining leading brands from both businesses.

  Action taken

  Panadol was placed in the new joint venture alongside brands including Advil, Sensodyne, Voltaren and Centrum.

  Aftermath

  The venture became Haleon and was subsequently separated from GSK as an independent listed company.

  Combined annual sales at formation. approximately £10 billion (2019-2022 corporate planning period)

  Source

• 1994

  SmithKline Beecham acquires Panadol owner SterlingM&A

  Background

  Sterling Drug owned the Panadol brand and was acquired by SmithKline Beecham as part of the latter’s consumer-health expansion.

  Action taken

  Panadol was incorporated into SmithKline Beecham’s international consumer-health portfolio.

  Aftermath

  The brand later passed into the GlaxoSmithKline and then Haleon corporate structures.

  Source

1. 1Haleon historyhaleon.com
2. 2GSK introduces Haleon to investorsgsk.com
3. 3GSK announces the Haleon namegsk.com
4. 4Haleon 2022 full-year resultshaleon.com
5. 5Panadol Release Starts Here campaignmarketing-beat.co.uk
6. 6Visible Manmarketingweek.com
7. 7Toughiesthisdaylive.com
8. 8Hit The Painadsoftheworld.com
9. 9More Laughs. Less Painconveniencestore.co.uk
10. 10Not that pain thoughadsoftheworld.com
11. 11Pain is Everywhereadsoftheworld.com
12. 12Art of Releaseadsoftheworld.com